ImmunoPrecise Antibodies (IPA) has released an update.
ImmunoPrecise Antibodies Ltd.’s subsidiary BioStrand is collaborating with PGxAI to develop an AI-driven pharmacogenomics model using their LENSai technology, aimed at personalizing medicine by predicting drug responses and reducing adverse reactions. This partnership intends to combine BioStrand’s AI expertise with PGxAI’s clinical insights to revolutionize prescription practices, ensuring more effective and safer therapies tailored to individual genetic profiles.
For further insights into IPA stock, check out TipRanks’ Stock Analysis page.
